-
The US FDA granted accelerated approval to Baiyueze® (Zebutinib) for the treatment of relapsed or refractory marginal zone lymphoma
Time of Update: 2021-11-05
After Baiyueze® monotherapy, 20% of patients achieved complete remissionBaiyueze® is generally well tolerated and is consistent with its known safety characteristicsBeijing, China and Cambridge, Massachusetts, September 15, 2021/PRNewswire/ - BeiGene (Nasdaq: BGNE; Hong Kong Stock Exchange: 06160) is a global biopharmaceutical company focused on Develop and commercialize innovative drugs worldwide .
-
5 kinds of anti-tumor drug instructions add children's drug information
Time of Update: 2021-11-05
Recently, the official website of the State Food and Drug Administration issued an announcement stating that the domestically marketed cisplatin injections, ifosfamide for injection, azathioprine tablets, asparaginase for injection and vindesine sulfate for injection, 5 anti-tumor drugs correspond to For specifications, please refer to the announcement request to submit a supplementary application for revision of the instructions to add information on children's medications .
-
Pfizer's oral JAK inhibitor Xeljanz receives two new indications in the EU
Time of Update: 2021-11-05
CompilationTom LeeA few days ago, the European Commission (EC) announced the approval of Pfizer’s JAK inhibitor oral drug Xeljanz (tofacitinib) for the treatment of young children with active polyarticular joints who are two years of age and older who have first used anti-rheumatic drugs (DMARDs) and have poor response to treatment.
-
CSPC will win $9 billion star anticoagulant
Time of Update: 2021-11-05
In 2020, Bristol-Myers Squibb’s Eliquis global sales exceeded 9 billion U.
In 2020, Bristol-Myers Squibb's Eliquis (apixaban tablets) global sales exceeded 9.
Bristol-Myers Squibb Eliquis global sales (unit: million dollars)Source: Mynet.
-
Pfizer announces voluntary recall of all batches of smoking cessation drug varenicline in the U.S.
Time of Update: 2021-11-05
He also stated that the health benefits of quitting smoking outweigh the theoretical potential carcinogenic risk of nitrosamine impurities in varenicline .
In 2020, Chantix generated sales of US$919 million for Pfizer, a year-on-year decrease of approximately 17.
-
Merck is sued by insurance company for delaying the listing of generic cholesterol drug Zetia
Time of Update: 2021-11-05
The two insurance companies accused Merck of using a "monopoly plan" to delay the listing of a generic drug for the blockbuster cholesterol drug Zetia, causing insurance companies to pay higher prices for the drug over the years .
-
US$6.5 billion acquisition of the company to obtain Johnson & Johnson's new FcRn antibody drug approved for clinical use in China
Time of Update: 2021-11-05
Text|Pharmaceutical Mission HillsThe Center for Drug Evaluation (CDE) of the National Medical Products Administration of China revealed that the new class 1 drug nipocalimab injection declared by Johnson & Johnson's Janssen company has obtained a clinical trial implied license, and plans to develop a treatment for systemic type.
-
21 provinces!
Time of Update: 2021-11-05
The summary is as follows:Fujian ProvinceFujian ProvinceOn September 28, the Fujian Provincial Medical Insurance Bureau and the Fujian Provincial Health Commission issued the "Notice on Implementing the Fifth Batch of National Organizations for Centralized Procurement and Use of Drugs", announcing that the fifth batch of nationally selected 61 selected varieties will be held in October 2021.
-
Hisun Pharmaceutical's Valsartan Tablets Passed the Consistency Evaluation of Generic Drugs
Time of Update: 2021-11-05
On August 23, Hisun Pharmaceutical issued an announcement stating that the company had recently received the "Drug Registration Certificate" for valsartan tablets approved and issued by the State Drug Administration .
-
Kelun Pharmaceutical's Gadoxetate Disodium Injection Obtained Drug Registration Approval
Time of Update: 2021-11-05
After review, the drug meets the relevant requirements of drug registration, approved for registration, and issued a drug registration certificate for the detection of focal liver lesions .
Compared with other MRI contrast agents, it can improve the detection rate of focal liver lesions and the accuracy of qualitative diagnosis, especially for small lesions.
-
Phase 3 clinical success of AstraZeneca/Mersk’s PARP inhibitor Lynparza
Time of Update: 2021-11-05
Lynparza is a PARP inhibitor that was approved by the US FDA in May 2020 for the treatment of mCRPC patients who have undergone a new type of hormone therapy Zytiga or Xtandi (enzalutamide, enzalutamide) and who have a mutation in the HRR gene .
-
Qilu meets his rivals!
Time of Update: 2021-11-05
According to data from Meinenet, the sales of terminal esmolol injections in China's public medical institutions will exceed 700 million yuan in 2020, a year-on-year increase of 24.
-
Innovent announces that IBI351 (KRAS G12C inhibitor) Phase I/II clinical study has completed the first patient dosing
Time of Update: 2021-11-05
San Francisco, USA and Suzhou, China September 30, 2021/PRNewswire/ - Cinda Biopharmaceuticals (Hong Kong Stock Exchange stock code: 01801), a company dedicated to R&D, production and sales for the treatment of tumors, metabolic diseases, and its own A biopharmaceutical company that is an innovative drug for major diseases such as immunity, today announced that its KRAS G12C inhibitor IBI351 phase I/II clinical study (ClinicalTrials.
-
Enhua broke out!
Time of Update: 2021-11-05
Figure 1: New drugs declared by Enhua since 2021Source: CDE official websiteAccording to data from Mi Nei. com, in 2020, in China’s urban public hospitals, county-level public hospitals, urban community centers, and township health centers (referred to as Chinese public medical institutions) terminals, Jiangsu Enhua Pharmaceutical has 7 varieties with sales of over 100 million yuan.
-
Talking about FGFR Inhibitors from the Combination Mode
Time of Update: 2021-11-05
From the eutectic structure with FGFR1 (Figure 2 right), it can be found that the dimethoxybenzene ring of PD173074 occupies the hydrophobic pocket in the ATP binding pocket through van der Waals interaction, and one of the methoxy groups forms a hydrogen bond with Asp641 .
-
Yatron Pharmaceuticals: Dr. Xinjie Chu served as CSO and Ms. Zhou Xin served as Vice President of Clinical R&D
Time of Update: 2021-11-05
Later, she established the Clinical Research Center of Xinhua Hospital Affiliated to Shanghai Jiaotong University School of Medicine and served as the executive director of the center .
-
Stabilizing the Boundary of the Fuzzy Volume of the Drug Use Structure——The Deep Meaning of the Volume Purchase of Guangdong Chemical Drugs
Time of Update: 2021-11-05
Following the renewal of contract 45 and 58 Chinese patent medicines, Guangdong’s largest volume of 153 chemical drugs and therapeutic biological products with the same generic name (that is, the same species) with large consumption and high purchase amount, the draft for comments on the procurement plan for the national day Finally surfaced the night before .
-
STSA-1005 injection, a wholly-owned subsidiary of Shutaishen, obtained clinical trial approval from the U.S. FDA
Time of Update: 2021-11-05
STSA-1005 specifically binds to human GMRα and blocks its interaction with the ligand GM-CSF, thereby negatively regulating the innate immune response .
STSA-1005 injection is independently developed by the company's wholly-owned subsidiary Stadson BioPharma Inc.
-
Hisun Pharmaceutical's insulin aspart injection was officially approved for the treatment of diabetes
Time of Update: 2021-11-05
Insulin aspart is a fast-acting analogue of human insulin, designed to control hyperglycemia caused by meals in diabetic patients requiring insulin treatment.
Later, it promotes glucose absorption while inhibiting the release of liver glycogen.
Compared with soluble human insulin, the subcutaneous absorption rate is faster .
-
Yangtze River's big move?
Time of Update: 2021-11-05
Currently, 15 innovative drugs (14 are category 1 new drugs) are in the clinical application and above stage; 79 have been reviewed The varieties (22 are the first ones) are eye-catching, helping the company to harvest a lot in centralized procurement; 76 new classifications are under review, and 20 have not been approved for the first copy .
